Is Any Consideration a “Payment”? The Continuing Struggle over How to Interpret FTC v. Actavis
Bloomberg BNA has published “Is Any Consideration a ‘Payment’? The Continuing Struggle over How to Interpret FTC v. Actavis,” written by Antitrust Partner Laura Shores and Complex Commercial Litigation Counsel Karin Garvey.
The article assesses the effects of the US Supreme Court decision regarding “reverse payment” settlements in branded-generic drug manufacturer patent litigation. The authors note that with little guidance in the initial decision issued slightly more than a year ago, lower courts are grappling with the threshold question, and, predictably, have reached different conclusions.
“A clear resolution is unlikely until the Supreme Court revisits the issue,” the authors conclude. “Until then, parties settling pharmaceutical patent litigation should be prepared for challenges to any settlement that involves more than an agreement on a generic entry date before patent expiration.”
Also of Interest
- Benchmark Litigation Recognizes Kaye Scholer Practices and Partners Nationwide October 24, 2016 • Recognitions
- Kaye Scholer Clients Achieve Nearly Full Recovery in Arch Coal Chapter 11 Proceeding October 14, 2016 • Client Successes
- GIR 100 Names Kaye Scholer a World Leader in Cross-Border Investigations October 10, 2016 • Recognitions
- Antitrust Jurisprudence in the Second Circuit October 1, 2016 • Articles
- NLJ Names Shores as Antitrust Trailblazer September 27, 2016 • Recognitions
- Morgenstern, Patterson Assess Second Circuit’s Antitrust Legacy in Fordham Law Review September 19, 2016 • Articles
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes
- Doing Deals with Competitors: Beware of Taking Minority Equity Stakes or Board Seats August 24, 2016 • Articles